search
Back to results

PF-07284892 in Participants With Advanced Solid Tumors

Primary Purpose

Solid Tumor

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
PF-07284892
lorlatinib
binimetinib
cetuximab
encorafenib
Sponsored by
Pfizer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Solid Tumor focused on measuring colorectal cancer, non-small cell lung cancer, B-type Raf proto-oncogene (BRAF) mutation, Ras mutation, anaplastic lymphoma kinase (ALK)-positive, neurofibromatosis type 1 (NF1), ROS1

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥18 years at the time of informed consent
  • Histological or cytological diagnosis of ALK-positive advanced NSCLC, CRC with BRAF V600E mutation, or RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumor. Participants with ROS-positive NSCLC are also eligible for Part 1 and 2
  • Documentation evidence of biomarker mutation status
  • Part 3:

ALK-positive NSCLC with prior lorlatinib and no prior platinum-based chemotherapy (Cohort 1); with prior lorlatinib and prior platinum-based chemotherapy (Cohort 2); or with no prior lorlatinib (Cohort 3).

BRAF V600E mutant CRC participants resistant to BRAFi plus EGFRi (Cohort 4 ); refractory to BRAFi plus EGFRi (Cohort 5); or BRAFi plus EGFRi naïve (Cohort 6).

RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumors who have received prior SOC (Cohort 7).

Exclusion Criteria:

  • Brain metastasis larger than 4 cm
  • Active malignancy within 3 years
  • Systemic anti-cancer therapy or small molecule therapeutics within 2 weeks prior to start of study treatment. Antibody based agents within 4 weeks prior to start of study treatment. Mitomycin C or nitrosoureas within 6 weeks prior to start of study treatment.
  • For participants who may get lorlatinib or encorafenib on study, history of interstitial lung disease
  • For participants who may get binimetinib on study, history or current evidence of retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with elevated creatine kinase (CK)

Sites / Locations

  • Mayo Clinic in Arizona - PhoenixRecruiting
  • Mayo ClinicRecruiting
  • California Cancer Associates for Research and ExcellenceRecruiting
  • California Cancer Associates for Research and ExcellenceRecruiting
  • University of IowaRecruiting
  • Henry Ford HospitalRecruiting
  • START MidwestRecruiting
  • Henry Ford Medical Center - ColumbusRecruiting
  • Mayo Clinic in Rochester, MinnesotaRecruiting
  • Memorial Sloan Kettering Cancer Center David H Koch Center for Cancer CareRecruiting
  • Memorial Sloan Kettering Cancer Center Rockefeller Outpatient PavilionRecruiting
  • Tennessee Oncology, PLLCRecruiting
  • Tennessee Oncology PLLCRecruiting
  • Tennessee Oncology, PLLCRecruiting
  • The University of Texas MD Anderson Cancer CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

PF-07284892 monotherapy

PF-07284892 in combination with lorlatinib (Part 2)

Expansion Phase (Cohort 1)

Expansion Phase (Cohort 2)

Expansion Phase (Cohort 3)

Expansion Phase (Cohort 4)

Expansion Phase (Cohort 5)

PF-07284892 in combination with encorafenib and cetuximab (Part 2)

PF-07284892 in combination with binimetinib (Part 2)

Arm Description

Monotherapy dose escalation of PF-07284892 in participants with ALK- or ROS1-positive non-small cell lung cancer (NSCLC), B-type Raf proto-oncogene V600E mutation colorectal cancer (CRC), or RAS- mutant, NF1-mutant or BRAF class 3-mutant solid tumors

Combination dose escalation of PF-07284892 in combination with lorlatinib in participants with ALK- or ROS1-positive NSCLC

PF-07284892 + lorlatinib in participants with ALK+ NSCLC with prior lorlatinib

PF-07284892 + lorlatinib in participants with ALK+ NSCLC with no prior lorlatinib

PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC with prior BRAF inhibitor (BRAFi) plus epidermal growth factor receptor inhibitor (EGFRi)

PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC with no prior BRAFi plus EGFRi

PF-07284892 + binimetinib in participants with RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumors who have received prior standard of care (SOC)

Combination dose escalation of PF-07284892 in combination with encorafenib and cetuximab in participants with BRAF V600E mutant CRC

Combination dose escalation of PF-07284892 in combination with binimetinib in participants with Ras-mutant, NF-1 mutant or BRAF class 3 -mutant solid tumors

Outcomes

Primary Outcome Measures

Part 1 and Part 2- Number of participants with dose limiting toxicities (DLTs)
DLTs will be evaluated during the first cycle (21 days) as both a single agent or in combination with lorlatinib, encorafenib + cetuximab, or binimetinib. The number of DLTs will be used to determine the maximum tolerated dose (MTD)/recommended dose for further study
Part 1 and Part 2- Number of participants with treatment-emergent adverse events (AEs)
AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy
Part 1 and Part 2 - Number of participants with clinically significant change from baseline in laboratory abnormalities
Laboratory abnormalities as characterized by type, frequency, severity, and timing
Part 1 and Part 2 - Number of dose interruptions, dose modifications, and discontinuations due to AEs
Incidence of dose interruptions, dose modifications, and discontinuations due to AEs
Part 3- Overall response
Response will be evaluated via radiographical tumor assessments by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

Secondary Outcome Measures

Part 1 and Part 2- Maximum plasma concentration (Cmax) of PF-07284892 and metabolite
single dose (Cmax) and multiple dose (assuming steady state is achieved; Css,max) pharmacokinetic (PK) parameters
Part 1 and Part 2- Time to reach maximum plasma concentration (Tmax) of PF-07284892 and metabolite
Single dose (Tmax) and multiple dose (assuming steady state is achieved; Tss,max) pharmacokinetic parameters
Part 1 and Part 2- Area under the plasma concentration-time curve from time 0 to the last time point of quantifiable concentration (AUClast) of PF-07284892 and metabolite
Single dose PK parameter
Part 1 and Part 2- Area under the plasma concentration-time curve from time 0 to extrapolated to infinity (AUCinf) of PF-07284892 and metabolite
Single dose and multiple dose (assuming steady state is achieved) PK parameter
Part 1 and Part 2- Metabolite ratio of PF-07284892 and metabolite
Single dose PK parameter
Part 1 and Part 2- Area under the plasma concentration-time curve from 0 to 24 (AUC24) or 48 hours (AUC48) of PF-07284892 and metabolite
Multiple dose (assuming steady state is achieved) PK parameter
Part 1 and Part 2- Overall response
Response will be evaluated via radiographical tumor assessments by RECIST v1.1
Part 2- Duration of Response (DOR)
Time from the first documentation of objective response to the first documentation of objective progressive disease, relapse or to death due to any cause

Full Information

First Posted
March 9, 2021
Last Updated
September 8, 2023
Sponsor
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT04800822
Brief Title
PF-07284892 in Participants With Advanced Solid Tumors
Official Title
A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EVIDENCE OF ANTI-TUMOR ACTIVITY OF PF-07284892 (ARRY-558) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 17, 2021 (Actual)
Primary Completion Date
June 4, 2024 (Anticipated)
Study Completion Date
December 4, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this first-in-patient, open label study is to determine the maximum tolerated dose and/or recommended dose for further study of PF-07284892 as a single agent and in combination with lorlatinib, encorafenib and cetuximab, or binimetinib and evaluate the pharmacokinetics, safety, and preliminary clinical activity of single agent and each combination therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumor
Keywords
colorectal cancer, non-small cell lung cancer, B-type Raf proto-oncogene (BRAF) mutation, Ras mutation, anaplastic lymphoma kinase (ALK)-positive, neurofibromatosis type 1 (NF1), ROS1

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
196 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
PF-07284892 monotherapy
Arm Type
Experimental
Arm Description
Monotherapy dose escalation of PF-07284892 in participants with ALK- or ROS1-positive non-small cell lung cancer (NSCLC), B-type Raf proto-oncogene V600E mutation colorectal cancer (CRC), or RAS- mutant, NF1-mutant or BRAF class 3-mutant solid tumors
Arm Title
PF-07284892 in combination with lorlatinib (Part 2)
Arm Type
Experimental
Arm Description
Combination dose escalation of PF-07284892 in combination with lorlatinib in participants with ALK- or ROS1-positive NSCLC
Arm Title
Expansion Phase (Cohort 1)
Arm Type
Experimental
Arm Description
PF-07284892 + lorlatinib in participants with ALK+ NSCLC with prior lorlatinib
Arm Title
Expansion Phase (Cohort 2)
Arm Type
Experimental
Arm Description
PF-07284892 + lorlatinib in participants with ALK+ NSCLC with no prior lorlatinib
Arm Title
Expansion Phase (Cohort 3)
Arm Type
Experimental
Arm Description
PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC with prior BRAF inhibitor (BRAFi) plus epidermal growth factor receptor inhibitor (EGFRi)
Arm Title
Expansion Phase (Cohort 4)
Arm Type
Experimental
Arm Description
PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC with no prior BRAFi plus EGFRi
Arm Title
Expansion Phase (Cohort 5)
Arm Type
Experimental
Arm Description
PF-07284892 + binimetinib in participants with RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumors who have received prior standard of care (SOC)
Arm Title
PF-07284892 in combination with encorafenib and cetuximab (Part 2)
Arm Type
Experimental
Arm Description
Combination dose escalation of PF-07284892 in combination with encorafenib and cetuximab in participants with BRAF V600E mutant CRC
Arm Title
PF-07284892 in combination with binimetinib (Part 2)
Arm Type
Experimental
Arm Description
Combination dose escalation of PF-07284892 in combination with binimetinib in participants with Ras-mutant, NF-1 mutant or BRAF class 3 -mutant solid tumors
Intervention Type
Drug
Intervention Name(s)
PF-07284892
Other Intervention Name(s)
ARRY-558
Intervention Description
PF-07284892
Intervention Type
Drug
Intervention Name(s)
lorlatinib
Other Intervention Name(s)
Lorbrena; PF-06463922, Lorviqua
Intervention Description
lorlatinib
Intervention Type
Drug
Intervention Name(s)
binimetinib
Other Intervention Name(s)
Mektovi, PF-06811462, MEK162
Intervention Description
binimetinib
Intervention Type
Biological
Intervention Name(s)
cetuximab
Other Intervention Name(s)
Erbitux
Intervention Description
cetuximab
Intervention Type
Drug
Intervention Name(s)
encorafenib
Other Intervention Name(s)
Braftovi, PF-07263896, LGX818
Intervention Description
encorafenib
Primary Outcome Measure Information:
Title
Part 1 and Part 2- Number of participants with dose limiting toxicities (DLTs)
Description
DLTs will be evaluated during the first cycle (21 days) as both a single agent or in combination with lorlatinib, encorafenib + cetuximab, or binimetinib. The number of DLTs will be used to determine the maximum tolerated dose (MTD)/recommended dose for further study
Time Frame
Cycle 1 (21 days)
Title
Part 1 and Part 2- Number of participants with treatment-emergent adverse events (AEs)
Description
AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy
Time Frame
Baseline up to 30 days after last dose of study medication
Title
Part 1 and Part 2 - Number of participants with clinically significant change from baseline in laboratory abnormalities
Description
Laboratory abnormalities as characterized by type, frequency, severity, and timing
Time Frame
Baseline up to 30 days after last dose of study treatment
Title
Part 1 and Part 2 - Number of dose interruptions, dose modifications, and discontinuations due to AEs
Description
Incidence of dose interruptions, dose modifications, and discontinuations due to AEs
Time Frame
Baseline up to 30 days after the last dose of study medication
Title
Part 3- Overall response
Description
Response will be evaluated via radiographical tumor assessments by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Time Frame
Baseline to up to 2 years
Secondary Outcome Measure Information:
Title
Part 1 and Part 2- Maximum plasma concentration (Cmax) of PF-07284892 and metabolite
Description
single dose (Cmax) and multiple dose (assuming steady state is achieved; Css,max) pharmacokinetic (PK) parameters
Time Frame
Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; end of treatment (EOT)
Title
Part 1 and Part 2- Time to reach maximum plasma concentration (Tmax) of PF-07284892 and metabolite
Description
Single dose (Tmax) and multiple dose (assuming steady state is achieved; Tss,max) pharmacokinetic parameters
Time Frame
Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; EOT
Title
Part 1 and Part 2- Area under the plasma concentration-time curve from time 0 to the last time point of quantifiable concentration (AUClast) of PF-07284892 and metabolite
Description
Single dose PK parameter
Time Frame
Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; EOT
Title
Part 1 and Part 2- Area under the plasma concentration-time curve from time 0 to extrapolated to infinity (AUCinf) of PF-07284892 and metabolite
Description
Single dose and multiple dose (assuming steady state is achieved) PK parameter
Time Frame
Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; EOT
Title
Part 1 and Part 2- Metabolite ratio of PF-07284892 and metabolite
Description
Single dose PK parameter
Time Frame
Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; EOT
Title
Part 1 and Part 2- Area under the plasma concentration-time curve from 0 to 24 (AUC24) or 48 hours (AUC48) of PF-07284892 and metabolite
Description
Multiple dose (assuming steady state is achieved) PK parameter
Time Frame
Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; EOT
Title
Part 1 and Part 2- Overall response
Description
Response will be evaluated via radiographical tumor assessments by RECIST v1.1
Time Frame
Baseline to up to 2 years
Title
Part 2- Duration of Response (DOR)
Description
Time from the first documentation of objective response to the first documentation of objective progressive disease, relapse or to death due to any cause
Time Frame
Baseline to up to 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥18 years at the time of informed consent Histological or cytological diagnosis of ALK-positive advanced NSCLC, CRC with BRAF V600E mutation, or RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumor. Participants with ROS-positive NSCLC are also eligible for Part 1 and 2 (Other ROS1-positive solid tumors may be considered after discussion with the sponsor). Documentation evidence of biomarker mutation status Part 3: ALK-positive NSCLC with prior lorlatinib and no prior platinum-based chemotherapy (Cohort 1); with prior lorlatinib and prior platinum-based chemotherapy (Cohort 2); or with no prior lorlatinib (Cohort 3). BRAF V600E mutant CRC participants resistant to BRAFi plus EGFRi (Cohort 4 ); refractory to BRAFi plus EGFRi (Cohort 5); or BRAFi plus EGFRi naïve (Cohort 6). RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumors who have received prior SOC (Cohort 7). Exclusion Criteria: Brain metastasis larger than 4 cm Active malignancy within 3 years Systemic anti-cancer therapy or small molecule therapeutics within 2 weeks prior to start of study treatment. Antibody based agents within 4 weeks prior to start of study treatment. Mitomycin C or nitrosoureas within 6 weeks prior to start of study treatment. For participants who may get lorlatinib or encorafenib on study, history of interstitial lung disease For participants who may get binimetinib on study, history or current evidence of retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with elevated creatine kinase (CK)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pfizer CT.gov Call Center
Phone
1-800-718-1021
Email
ClinicalTrials.gov_Inquiries@pfizer.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Mayo Clinic in Arizona - Phoenix
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85054
Country
United States
Individual Site Status
Recruiting
Facility Name
Mayo Clinic
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85259
Country
United States
Individual Site Status
Recruiting
Facility Name
California Cancer Associates for Research and Excellence
City
Encinitas
State/Province
California
ZIP/Postal Code
92024
Country
United States
Individual Site Status
Recruiting
Facility Name
California Cancer Associates for Research and Excellence
City
San Marcos
State/Province
California
ZIP/Postal Code
92069
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Iowa
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
Individual Site Status
Recruiting
Facility Name
Henry Ford Hospital
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Individual Site Status
Recruiting
Facility Name
START Midwest
City
Grand Rapids
State/Province
Michigan
ZIP/Postal Code
49546
Country
United States
Individual Site Status
Recruiting
Facility Name
Henry Ford Medical Center - Columbus
City
Novi
State/Province
Michigan
ZIP/Postal Code
48377
Country
United States
Individual Site Status
Recruiting
Facility Name
Mayo Clinic in Rochester, Minnesota
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Individual Site Status
Recruiting
Facility Name
Memorial Sloan Kettering Cancer Center David H Koch Center for Cancer Care
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Individual Site Status
Recruiting
Facility Name
Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavilion
City
New York
State/Province
New York
ZIP/Postal Code
10022
Country
United States
Individual Site Status
Recruiting
Facility Name
Tennessee Oncology, PLLC
City
Franklin
State/Province
Tennessee
ZIP/Postal Code
37067
Country
United States
Individual Site Status
Recruiting
Facility Name
Tennessee Oncology PLLC
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Recruiting
Facility Name
Tennessee Oncology, PLLC
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Recruiting
Facility Name
The University of Texas MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Links:
URL
https://pmiform.com/clinical-trial-info-request?StudyID=C4481001
Description
To obtain contact information for a study center near you, click here.

Learn more about this trial

PF-07284892 in Participants With Advanced Solid Tumors

We'll reach out to this number within 24 hrs